Recombinant Human FABP4 protein (His Tag)
种属
Human
纯度
>90 %, SDS-PAGE
标签
His Tag
生物活性
未测试
验证数据展示
产品信息
纯度 | >90 %, SDS-PAGE |
内毒素 | <0.1 EU/μg protein, LAL method |
生物活性 |
Not tested |
来源 | HEK293-derived Human FABP4 protein Cys2-Ala132 (Accession# P15090) with a His tag at the C-terminus. |
基因ID | 2167 |
蛋白编号 | P15090 |
预测分子量 | 15.7 kDa |
SDS-PAGE | 13-15 kDa, reducing (R) conditions |
组分 | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
复溶 | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
储存条件 |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
运输条件 | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
背景信息
Fatty acid binding protein (FABP) 4 is a member of the FABP family which abundantly expressed, fatty acid carrier proteins. FABPs are capable of binding a variety of hydrophobic molecules such as long-chain fatty acids and are important for their uptake and intracellular trafficking. It was first identified as an adipocyte-specific protein, important for the maintenance of lipid and glucose metabolism. It is also detected in macrophages, where it participates in regulating inflammation and cholesterol trafficking via NFκB and PPAR. In more recent studies, FABP4 has been found in a variety of endothelial cells, where it has been identified as a target of VEGF and a regulator of cell proliferation and possibly angiogenesis. Pathologically, FABP4 has been associated with the development of metabolic syndrome, diabetes and cancer and vulnerability of atherosclerotic plaques. FABP4 has been identified as a novel prognostic factor for both adverse cardiovascular events and breast cancer.
参考文献:
1.Lai W, et al. (2022)Eur J Pharmacol. 931:175224. 2.Floresta G, et al. (2022)Eur J Med Chem. 240:114604. 3.Furuhashi M, et al. (2014). Clin Med Insights Cardiol.8 (Suppl 3):23-33. 4.Furuhashi M. (2019) J Atheroscler Thromb. 26 (3):216-232.